Skip to main content

ASCPT 2025 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

I
PII-049
IDENTIFYING FUNCTIONAL REGULATORY SNPS THAT REGULATE CYP2C9 EXPRESSION TO OPTIMIZE CYP2C9 BIOMARKER PANELS.

Favorite
PI-049
IMPACT OF CYP2C19 AND CYP3A INHIBITORS ON CLOPIDOGREL CLINICAL EFFECTIVENESS IN CYP2C19 GENOTYPED PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN A REAL-WORLD SETTING.

Favorite
PI-070
IMPACT OF EAST ASIAN ETHNICITY ON PHARMACOKINETICS OF SOTATERCEPT

Favorite
PI-015
IMPACT OF RIFAMPICIN DOSE ON LINEZOLID PHARMACOKINETICS IN TUBERCULOUS MENINGITIS: INSIGHTS FROM THE ALTER TRIAL

Favorite
PI-109
IMPACT OF RISK EVALUATION AND MITIGATION STRATEGY PROGRAMS ON PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT

Favorite
PII-050
IMPACT OF SOCIAL DETERMINANTS OF HEALTH COMPOSITE MEASURES ON OUTCOMES AFTER PCI IN P2Y12 INHIBITOR-TREATED PATIENTS

Favorite
PI-023
INCORPORATING HEPATIC TRANSPORTER ZONATION INTO PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS: IMPLICATIONS FOR PRAVASTATIN DISPOSITION IN WHITE AND CHINESE POPULATIONS CONSIDERING OATP1B1 PHENOTYPES.

Favorite
PI-050
INFLUENCE OF ALDH2 RS671 POLYMORPHISM ON ANTIBODY TITER AFTER INFLUENZA VACCINATION: A PROSPECTIVE OBSERVATIONAL STUDY

Favorite
PII-031
INFORMATIVE CENSORING BIAS IN DOSE-RESPONSE ANALYSIS OF PROGRESSION-FREE SURVIVAL OF ANTICANCER DRUGS

Favorite
PII-071
INTEGRATED MODEL BASED ANALYSES OF MILVEXIAN PHASE 2 SSP TRIAL DATA SUPPORTS PHASE 3 DOSE SELECTION

Favorite
PWII-003
INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.

Favorite
PT-004
INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.

Favorite
PI-018
INTERPLAY BETWEEN HIV AND METHADONE: EFFECTS ON CHEMOKINE DYSREGULATION AND NEUROINFLAMMATION.

Favorite
PII-018
INTESTINAL MICROBIOME AND METABOLOME FLUCTUATIONS IN PATIENTS RECEIVING INTENSE CHEMOTHERAPY FOR AML: RESULTS FROM A PILOT, PROSPECTIVE OBSERVATIONAL STUDY

Favorite
PT-021
IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.

Favorite
PWI-004
IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.

Favorite
PII-005
ITPA ACTIVITY TO PREDICT REMISSION WITH METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS

Favorite